Viz.ai Partners with Sanofi and Regeneron to Deploy AI-Powered COPD Management Solution
核心洞察
Viz.ai (搜索) has entered a multi-year collaboration with Sanofi and Regeneron to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (搜索) management.
The Viz COPD (搜索) module will leverage electronic health record data and natural language processing to identify and triage high-risk COPD patients according to established clinical guidelines.
The collaboration addresses significant unmet needs in COPD (搜索) care, targeting a disease that affects 392 million people globally and represents the fourth leading cause of death worldwide.
Viz.ai (搜索), a leader in AI-powered disease detection and intelligent care coordination, has announced a multi-year partnership with pharmaceutical giants Sanofi and Regeneron to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (搜索) (COPD (搜索)) management. The collaboration will focus on testing the Viz COPD module, a care acceleration solution designed to leverage electronic health record (EHR) data and artificial intelligence to advance the detection and management of high-risk COPD patients.
Addressing Critical Unmet Medical Needs
COPD (搜索) represents a significant global health challenge, affecting an estimated 392 million people worldwide and ranking as the fourth leading cause of death globally. The progressive lung disease results in restricted airflow, making breathing difficult for patients. Beyond its clinical impact, COPD places substantial strain on healthcare systems, with healthcare utilization growing as symptoms progress, magnifying the economic toll of the disease.
"At Sanofi, we're excited to collaborate with Viz.ai (搜索) to further address unmet needs in COPD (搜索) care by leveraging AI," said Paul Rowe, MD, ATSF & Head of Medical, Specialty Care at Sanofi. "With this collaboration, we will study the impact of the Viz COPD module, a streamlined AI-enabled EHR workflow to improve access to care and ultimately patient outcomes in COPD, a disease that remains underprioritized, underfunded and undertreated in comparison to other noncommunicable diseases."
AI-Powered Clinical Decision Support
The Viz COPD (搜索) module will evaluate EHR data using natural language processing to screen and triage patients in line with established clinical guidelines, flagging high-risk individuals for further follow-up and care. Many COPD patients currently fail to receive optimal treatment due to improper identification of risk level, poor care coordination, lack of monitoring and escalation, and high administrative barriers to therapy.
The solution is designed to assess EHR data through natural language processing, aligning with established clinical guidelines to screen and triage subjects, and highlighting those at elevated risk for further care and follow-up. This approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes.
Leveraging Established Healthcare Network
The Viz COPD (搜索) module builds upon Viz.ai (搜索)'s existing presence across more than 1,700 hospitals and health systems, engaging over 60,000 healthcare providers on the platform to improve diagnosis and care across various disease areas, including respiratory conditions. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with suspected diseases, informs critical decisions at the point of care, and optimizes care pathways to help improve outcomes.
"This collaboration with Sanofi and Regeneron is a major step forward in our mission to expand AI-driven care coordination across disease areas with critical unmet needs, such as COPD (搜索)," said Chris Mansi, MD, CEO and co-founder of Viz.ai (搜索). "Our approach aims to empower healthcare providers to deliver data-driven, guideline-directed care that meaningfully impacts patient outcomes. We look forward to collaborating with Sanofi and Regeneron to harness AI to accelerate advancements in disease management and improve patient access to care."
Clinical Impact and Future Implications
The partnership between the three companies is positioned to maximize patient impact, particularly for patients who stand to benefit most from improved follow-up and care coordination. Backed by real-world clinical evidence, the Viz.ai (搜索) One solution delivers significant value to patients, providers, and pharmaceutical and medical device companies.
Viz.ai (搜索) leverages machine learning and AI algorithms to expedite the diagnosis and care process across numerous hospitals and health systems in Europe and the United States. The collaboration represents a significant step forward in addressing the substantial care gaps that exist in COPD (搜索) management, potentially improving outcomes for millions of patients worldwide who currently receive suboptimal care due to system-level barriers and coordination challenges.